Access cutting-edge chronic urticaria treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Access chronic urticaria specialists in Little Rock at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic urticaria treatment provided free
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data o
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this chronic urticaria clinical trial in Little Rock, AR
If you're searching for chronic urticaria treatment options in Little Rock, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic urticaria specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.